RE:RE:Question ???Dubuc pretty clear the RD number will be around 2021's $28mil and overall opex will drop back to the 2021 level. It was $93mil 2022 and 2021 was around $72mil, so the general plan is save $20mil on expenses and see revenues grow $10-15mil for a net change of $30-35mil on EBITDA. That's pretty significant.
Give the 7% price rise for drugs already, the revenue should be at least low end. Sounds like there's a small bit of sales margin improvement as well given the loss-making Euro side is fully in 2022 numbers but will completely disappear in 2023. That's also a small help. Overall, these numbers seem very doable to get to the adj EBITDA breakeven. With a bit of luck you hit the high end of sales, control costs better, reassure on next years sales. To me, that gets you to $1.50-$2.00 level. Any other good news around in-licensing, partners, etc.. is upside, but market will want to see proof. I want to just get it back to a reasonable valuation based on revenues, breakeven and drug growth so we can recoup these losses. Paul seems determined to do that and sounded like he got that message from all the big shareholders, probably strongly, as a way to salvage their dud investment. If they execute, the share should respond in my opinion.